Cochrane · systematic review · CD003804
Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia
Areosa Sastre, A, Vernooij, RWM, González‐Colaço Harmand, M, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Dementia and Cognitive ImprovementAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
16
current version
GRADE rated
6
No studies
10
Included studies
NR
No studies 10 · 62.5%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 18.8%Moderate 3 · 18.8%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Glibenclamide (glyburide) compared to Repaglinide for Type 2 diabetes
Population: patients with Type 2 diabetes
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global cognitive function measured by MMSE at 12 months Glibenclamide (glyburide) vs Repaglinide | no estimate extracted | 1 study · 156 participants | Low Downgraded: risk of bias, imprecision |
Incidence of MCI Glibenclamide (glyburide) vs Repaglinide | no estimate extracted | NR | No studies |
Incidence of dementia Glibenclamide (glyburide) vs Repaglinide | no estimate extracted | NR | No studies |
Adverse events (Hypoglycaemia) Glibenclamide (glyburide) vs Repaglinide | no estimate extracted | NR | No studies |
Mortality Glibenclamide (glyburide) vs Repaglinide | no estimate extracted | NR | No studies |
Intensive glycaemic control compared to standard glycaemic control for Type 2 diabetes
Population: patients with Type 2 diabetes
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global cognitive function (defined as reduction of at least 3 points in MMSE) Intensive glycaemic control vs standard glycaemic control | RR 0.98 [0.88, 1.08] | 1 study · 11140 participants | Moderate Downgraded: risk of bias |
Global cognitive function measured by MMSE at 40 months Intensive glycaemic control vs standard glycaemic control | no estimate extracted | 1 study · 2794 participants | Moderate Downgraded: risk of bias |
Incidence of MCI Intensive glycaemic control vs standard glycaemic control | no estimate extracted | NR | No studies |
Incidence of dementia (defined as dementia according to DSM‐IV) Intensive glycaemic control vs standard glycaemic control | RR 1.27 [0.87, 1.85] | 1 study · 11140 participants | Low Downgraded: risk of bias |
Adverse events (Hypoglycaemia) Intensive glycaemic control vs standard glycaemic control | RR 2.18 [1.52, 3.14] | 2 studies · 12931 participants | Low Downgraded: risk of bias |
Mortality Intensive glycaemic control vs standard glycaemic control | RR 1 [0.79, 1.26] | 3 studies · 15888 participants | Moderate Downgraded: risk of bias |
Rosiglitazone plus metformin compared to glibenclamide (glyburide) plus metformin for Type 2 diabetes
Population: patients with Type 2 diabetes
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global cognitive function Rosiglitazone plus metformin vs glibenclamide (glyburide) plus metformin | no estimate extracted | NR | No studies |
Incidence of MCI Rosiglitazone plus metformin vs glibenclamide (glyburide) plus metformin | no estimate extracted | NR | No studies |
Incidence of dementia Rosiglitazone plus metformin vs glibenclamide (glyburide) plus metformin | no estimate extracted | NR | No studies |
Adverse events (Hypoglycaemia) Rosiglitazone plus metformin vs glibenclamide (glyburide) plus metformin | no estimate extracted | NR | No studies |
Mortality Rosiglitazone plus metformin vs glibenclamide (glyburide) plus metformin | no estimate extracted | NR | No studies |